Analyst Ratings for [INFI] Infinity Pharmaceuticals, Inc.

10/18/21	Initiated	Buy	X
INFI Infinity Pharmaceutical H.C. Wainwright
$9
7/28/21	Upgrades	Eq Weight Overweight	X
INFI Infinity Pharmaceutical Wells Fargo
$4 $14
7/7/21	Resumed	Buy	X
INFI Infinity Pharmaceutical B. Riley Securities
$7
3/18/21	Initiated	Buy	X
INFI Infinity Pharmaceutical Truist
$12
2/18/21	Initiated	Overweight	X
INFI Infinity Pharmaceutical Piper Sandler
$7
2/5/21	Upgrades	Underweight Neutral	X
INFI Infinity Pharmaceutical JP Morgan
6/27/19	Initiated	Outperform	X
INFI Infinity Pharmaceutical Oppenheimer
1/4/19	Initiated	Buy	X
INFI Infinity Pharmaceutical B. Riley FBR
$3
11/12/18	Downgrades	Neutral Underweight	X
INFI Infinity Pharmaceutical JP Morgan
11/12/18	Downgrades	Outperform Mkt Perform	X
INFI Infinity Pharmaceutical Wells Fargo

INFI Infinity Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.